Everything Totally Explained


Ask & we'll explain, totally!
Aciclovir
Totally Explained


  NEW! All the latest news in the worlds of computer gaming, entertainment, the environment,  
finance, health, politics, science, stocks & shares, technology and much, much, more.  


View this entry using RSS

Everything about Acyclovir totally explained

| PubChem = 2022 | DrugBank = APRD00567 | C=8 | H=11 | N=5 | O=3 | molecular_weight = 225.21 g/mol | melting_point = 256.5 | bioavailability = 10–20% (oral) | protein_bound = 9–33% | metabolism = Viral thymidine kinase | elimination_half-life = 2.2–20 hours | excretion = Renal | pregnancy_category = B3 (Au), B (U.S.) | legal_status = unscheduled/S4 (Au), POM (UK) | routes_of_administration = Intravenous, oral, topical }} Aciclovir (INN) or acyclovir (USAN, former BAN), chemical name acycloguanosine, is a guanine analogue antiviral drug, marketed under trade names such as Zovirax and Zovir (GSK). One of the most commonly-used antiviral drugs, it's primarily used for the treatment of herpes simplex virus infections, as well as in the treatment of herpes zoster (shingles).
   Aciclovir was seen as the start of a new era in antiviral therapy, as it's extremely selective and low in cytotoxicity. Pharmacologist Gertrude B. Elion was awarded the 1988 Nobel Prize in Medicine, partly for the development of acyclovir.

Pharmacology

Mechanism of action

Acylovir differs from previous nucleoside analogues in that it contains only a partial nucleoside structure: the sugar ring is replaced by an open-chain structure. It is selectively converted into acyclo-guanosine monophosphate (acyclo-GMP) by viral thymidine kinase, which is far more effective (3000 times) in phosphorylation than cellular thymidine kinase. Subsequently, the monophosphate form is further phosphorylated into the active triphosphate form, acyclo-guanosine triphosphate (acyclo-GTP), by cellular kinases. Acyclo-GTP is a very potent inhibitor of viral DNA polymerase; it has approximately 100 times greater affinity for viral than cellular polymerase. As a substrate, acyclo-GMP is incorporated into viral DNA, resulting in chain termination. It has also been shown that viral enzymes can't remove acyclo-GMP from the chain, which results in inhibition of further activity of DNA polymerase. Acyclo-GTP is fairly rapidly metabolised within the cell, possibly by cellular phosphatases.
   In sum, aciclovir can be considered a prodrug: it's administered in an inactive (or less active form) and is metabolised into a more active species after administration.

Microbiology

Acylovir is active against most species in the herpesvirus family. In descending order of activity:
Activity is predominantly against HSV, and to a lesser extent VZV. It is only of limited efficacy against EBV and CMV. It is inactive against latent viruses in nerve ganglia.
   To date, resistance to acyclovir hasn't been clinically significant. Mechanisms of resistance in HSV include deficient viral thymidine kinase; and mutations to viral thymidine kinase and/or DNA polymerase, altering substrate sensitivity.

Pharmacokinetics

Acylovir is poorly water soluble and has poor oral bioavailability (10–20%), hence intravenous administration is necessary if high concentrations are required. When orally administered, peak plasma concentration occurs after 1–2 hours. Acylovir has a high distribution rate, only 30% is protein-bound in plasma. The elimination half-life of aciclovir is approximately 3 hours. It is renally excreted, partly by glomerular filtration and partly by tubular secretion.
   The poor oral bioavailability may also be improved by administering Valaciclovir, which has a oral bioavailability of about 55%. Valaciclovir is then converted to Acylovir by esterases via hepatic first-pass metabolism.

Clinical use

Indications

Acylovir is indicated for the treatment of HSV and VZV infections, including:
  • Genital herpes simplex (treatment and prophylaxis)
  • Herpes simplex labialis (cold sores)
  • Herpes zoster (shingles)
  • Acute chickenpox in immunocompromised patients
  • Herpes simplex encephalitis
  • Acute mucocutaneous HSV infections in immunocompromised patients
  • Herpes simplex keratitis (ocular herpes)
  • Herpes simplex blepharitis (not to be mistaken with ocular herpes)
  • Bell's Palsy It has been claimed that the evidence for the effectiveness of topically applied cream for recurrent labial outbreaks is weak. Likewise oral therapy for episodes is inappropriate for most non-immunocompromised patients, whilst there's evidence for oral prophylactic role in preventing recurrences.

    Dosage forms

    Acyclovir is commonly marketed as tablets (200 mg, 400 mg and 800 mg), topical cream (5%), intravenous injection (25 mg/mL) and ophthalmic ointment (3%). Cream preparations are used primarily for labial herpes simplex. The intravenous injection is used when high concentrations of aciclovir are required. The ophthalmic ointment preparation is only used for herpes simplex keratitis.

    Adverse effects

    Systemic therapy

    Common adverse drug reactions (≥1% of patients) associated with systemic acyclovir therapy (oral or IV) include: nausea, vomiting, diarrhea and/or headache. In high doses, hallucinations have been reported. Infrequent adverse effects (0.1–1% of patients) include: agitation, vertigo, confusion, dizziness, oedema, arthralgia, sore throat, constipation, abdominal pain, rash and/or weakness. Rare adverse effects (<0.1% of patients) include: coma, seizures, neutropenia, leukopenia, crystalluria, anorexia, fatigue, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis and/or anaphylaxis. Additional common adverse effects, when acyclovir is administered IV, include encephalopathy (1% of patients) and injection site reactions. The injection formulation is alkaline (pH 11), and extravasation may cause local tissue pain and irritation. Renal impairment has been reported when acyclovir is given in large, fast doses intravenously, due to the crystallisation of acyclovir in the kidneys.

    Topical therapy

    Acyclovir topical cream is commonly associated (≥1% of patients) with: dry or flaking skin and/or transient stinging/burning sensations. Infrequent adverse effects include erythema and/or itch. When applied to the eye, acyclovir is commonly associated (≥1% of patients) with transient mild stinging. Infrequently (0.1–1% of patients), ophthalmic aciclovir is associated with superficial punctate keratitis and/or allergic reactions.

    Toxicity

    Since acyclovir can be incorporated also into the cellular DNA, it's a chromosome mutagen, therefore, its use should be avoided during pregnancy. However it hasn't been shown to cause any teratogenic nor carcinogenic effects. The acute toxicity (LD50) of aciclovir when given orally is greater than 1 g/kg, due to the low oral bioavailability.

    Footnotes

    Further Information

    Get more info on 'Acyclovir'.


    External Link Exchanges

    Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:

      <a href="http://aciclovir.totallyexplained.com">Aciclovir Totally Explained</a>

    Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
       As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned.



  • Copyright © 2007-8 totallyexplained.com | Licensed under the GNU Free Documentation License | Site Map
    This article contains text from the Wikipedia article Aciclovir (History) and is released under the GFDL | RSS Version